Comparative efficacy of switching to natalizumab in active multiple sclerosis (Q35469575)

8 August 2017

title

Comparative efficacy of switching to natalizumab in active multiple sclerosis (English)

1 reference

8 August 2017

Thor Petersen

0 references

Helmut Butzkueven

0 references

Alessandra Lugaresi

0 references

Heinz Wiendl

0 references

Maria Trojano

0 references

Ludwig Kappos

1 reference

8 August 2017

Guillermo Izquierdo

1 reference

8 August 2017

Pierre Duquette

1 reference

8 August 2017

Annie Zhang

1 reference

8 August 2017

Shibeshih Belachew

1 reference

8 August 2017

Freek Verheul

1 reference

8 August 2017

Francois Grand-Maison

object named as

Francois Grand-Maison

1 reference

8 August 2017

Jeannette Lechner-Scott

object named as

Jeannette Lechner-Scott

1 reference

8 August 2017

Celia Oreja-Guevara

1 reference

8 August 2017

Raymond Hupperts

1 reference

8 August 2017

Pierre Grammond

1 reference

8 August 2017

Michael Barnett

1 reference

8 August 2017

Timothy Spelman

1 reference

8 August 2017

Tomas Kalincik

1 reference

8 August 2017

Fabio Pellegrini

1 reference

8 August 2017

Larisa Tsvetkova

1 reference

8 August 2017

Robert Hyde

1 reference

8 August 2017

publication date

27 February 2015

1 reference

Annals of clinical and translational neurology

8 August 2017

published in

1 reference

8 August 2017

1 reference

8 August 2017

1 reference

8 August 2017

page(s)

373-387

1 reference

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Maximising therapeutic outcomes in patients failing on current therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Switching algorithms: from one immunomodulatory agent to another

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Risk of relapse phenotype recurrence in multiple sclerosis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4402083

The central role of the propensity score in observational studies for causal effects

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FACN3.180

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FACN3.180

Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25909083

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25909083

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25909083

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/ACN3.180

1 reference

8 August 2017

1 reference

8 August 2017

1 reference